Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CVS Health Seeks Return To LDL Treatment Targets To Control PCSK9s

This article was originally published in The Pink Sheet Daily

Executive Summary

Broad nature of latest cholesterol treatment guidelines makes it hard to deploy utilization management programs to control use of pricey new PCSK9 inhibitors, CVS Health argues in JAMA editorial.


Related Content

PCSK9 Coverage: Payers Wrestling With Proving Statin Intolerance
Praluent Coverage: Being First May Not Matter As Payers Await Repatha
Praluent Launch Brings Clinical Practice Challenges
Time, And Price, Are Right To Prescribe Statins To the Masses
Cholesterol Guidelines Look High And Low: Statin Market Extended At Both Ends


Related Companies

Related Deals

What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts